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Abstract
Background: Apigenin is a flavonoid widely distributed in plant kingdom that exerts cytotoxic effects against a
variety of solid and haematological cancers. In this study, we investigated the effect of apigenin against primary
effusion lymphoma (PEL), a KSHV-associated B cell lymphoma characterized by a very aggressive behavior, displaying
constitutive activation of STAT3 as well as of other oncogenic pathways and harboring wtp53.
Methods: Cell death was assessed by trypan blue exclusion assay, FACS analysis as well as by biochemical studies.
The latter were also utilized to detect the occurrence of autophagy and the molecular mechanisms leading to the
activation of both processes by apigenin. FACS analysis was used to measure the intracellular ROS utilizing DCFDA.
Results: We show that apigenin induced PEL cell death and autophagy along with reduction of intracellular ROS.
Mechanistically, apigenin activated p53 that induced catalase, a ROS scavenger enzyme, and inhibited STAT3, the most
important pro-survival pathway in PEL, as assessed by p53 silencing. On the other hand, STAT3 inhibition by apigenin
resulted in p53 activation, since STAT3 negatively influences p53 activity, highlighting a regulatory loop between these
two pathways that modulates PEL cell death/survival.
Conclusion: The findings of this study demonstrate that apigenin may modulate pro-apoptotic and pro-survival
pathways representing a valid therapeutic strategy against PEL.
Keywords: Apigenin, Apoptosis, Autophagy, KSHV, p53, PEL, STAT3, vFLIP
Background
Apigenin is one of the major flavonoids being present in
a variety of natural sources such as parsley, chamomile,
celery, artichokes, and oregano [1]. Several studies have
reported that apigenin can be used to prevent or suc-
cessfully control tumor progression in vivo, in several
animal models [2]. These effects have been shown to
occur either through the activation of the p53 oncosup-
pressor gene [2, 3] or the inhibition of oncogenic path-
ways, such as NFkB [4], HIF1alfa [5] and AKT [6]. The
latter has been reported to be a target of apigenin in Pri-
mary Effusion Lymphoma (PEL) cells [7]. PEL is a
Kaposi Sarcoma Associated Herpesvirus (KSHV)-associ-
ated malignant B cell lymphoma highly refractory to
conventional chemotherapies [8], but displaying a good
susceptibility to treatment with natural products such as
capsaicin [9, 10]. These molecules share the characteris-
tic to concomitantly inhibit multiple oncogenic pathways
such as AKT and STAT3, strongly involved in PEL cell
survival [11–13]. The latter indeed positively regulates
the expression of pro-survival molecules such as survi-
vin, cyclinD1 and c-myc [14, 15] or anti-apoptotic pro-
teins such as c-FLIP [16, 17].
Similarly to other flavonoids, apigenin has been re-
ported to target and to inhibit STAT3 in several cancers
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[18, 19] sometimes concomitantly with the activation of
p53 tumor suppressor functions [18], leading to reduc-
tion of cancer cell survival. Interestingly, it has been de-
scribed that activated STAT3 may inhibit p53, repressing
its pro-apoptotic activity [20] and that, on the other
hand, wtp53 activation may reduce STAT3 tyrosine
phosphorylation and interfere with its DNA binding ac-
tivity in prostate cancer cell lines displaying constitutive
STAT3 activation [21]. Furthermore, it has been re-
ported that the loss of p53 function activates JAK2-
STAT3 signaling to promote pancreatic tumor growth
and gemcitabine resistance [22]. All these studies suggest
a reciprocal influence between p53 and STAT3 in can-
cer. Based on this knowledge and on the reports show-
ing that apigenin can target both STAT3 and p53 in
cancer cells, in this study we investigated the effect of
apigenin in PEL cells that display constitutive STAT3 ac-
tivation and wtp53, and the underlying mechanisms
[21]. ROS, highly produced in cancer cells including
PEL, are essential for their survival since sustain the acti-
vation of STAT3 as well as of other oncogenic pathways.
Intracellular ROS can be regulated by wtp53 [23] that,
among its numerous activities, may reduce the intracel-
lular ROS by up-regulating catalase, one of the most im-
portant ROS scavenger [24] or other anti-oxidant
enzymes [25]. Thus, we next investigated whether ROS
reduction by apigenin could lead to STAT3 de-
phosphorylation and whether STAT3 inhibition could
down-regulate the expression of downstream molecules
such as c-myc and cyclin D1 that sustain cancer cell
proliferation and/or affect cellular or viral anti-apoptotic
molecules. Finally, we evaluated whether apigenin, previ-
ously reported to interfere with AKT activation, could
also affect autophagy in PEL cells.
Methods
Cell culture and reagents
BC3 (American Type Culture Collection, Manassas, Va,
USA; ATCC) and BCBL1 (kindly provided by Prof. P.
Monini, National AIDS Center, Istituto Superiore di
Sanità, Rome, Italy) are human B-cell lines infected by
KSHV, established from patients affected by Primary Ef-
fusion Lymphoma (PEL). Primary B lymphocytes were
obtained from healthy donors as previously described
[26]. Cells were cultured in RPMI 1640 (Thermo Fisher
Scientific, Waltham, MA, USA; 21,870) supplemented
with 10% Fetal Bovine Serum (FBS) (Corning, NY, USA;
35-079), with L-glutamine and with streptomycin
(100 μg/ml) (Corning, NY, USA; 30-002) and with peni-
cillin (100 U/ml) (Corning, NY, USA; 25-005) in 5% CO2
at 37 °C.
In dose-dependent studies, BC3 and BCBL-1 cell lines
were treated with apigenin (Api) (Sigma Aldrich, St
Louis. MO, USA; 520-36-5) at 12.5 μM and 25 μM or
with N-acetyl-L-cysteine (NAC) at 25 and 50μM (Sigma
Aldrich, St Louis. MO, USA; 616-91-1), for 24 h. PEL
cells were also cultured in a complete medium supple-
mented with AG490 (50 μM) (Calbiochem, Billerica,
MA, USA; 658,411) for 24 h.
In order to investigate autophagy, cells were cultured
in a complete medium with apigenin (12.5 μM) and after
24 h were treated with chloroquine (CQ) (10 μM) (Santa
Cruz Biotechnology Inc., Heidelberg, Germany; sc-
201,550), an inhibitor of vacuolar-H+-ATPase, for the
last four hours.
Cell viability
BC3, BCBL1 and B cells were plated in 12-well plates at
a density of 8 × 105 cells/well. Cells were treated in a
dose-dependent manner with apigenin (Sigma Aldrich,
St Louis. MO, USA; D150659;) at 12.5 μM and 25 μM
or with NAC at 25 μM and 50μM (Sigma Aldrich, St
Louis. MO, USA; 616-91-1), for 24 h. BC3 cells were
also transiently transfected with empty [27] vector or si-
p53 plasmid [28] as described below, and then treated
with apigenin (12.5 μM) for 24 h.
A trypan blue (Sigma Aldrich, St Louis. MO, USA;
72,571) exclusion assay was performed to test cell viabil-
ity. Live cells were counted by light microscopy using a
Neubauer hemocytometer. The experiments were per-
formed in triplicate and at least repeated three times.
Measurement of intracellular reactive oxygen species
(ROS) production
To measure reactive oxygen species (ROS) produc-
tion, the 2′,7′-dichlorofluorescein diacetate (DCFDA)
(Thermo Fisher Scientific, Waltham, MA, USA; D399)
was used. DCFDA is a fluorogenic dye that, after
diffusion in to the cell, is oxidized by ROS into 2′,7′-
dichlorofluorescein (DCF), a highly fluorescent com-
pound which can be detected by fluorescence spec-
troscopy. To measure ROS production, BC3 and
BCBL1 cells were treated with apigenin at 12.5 μM
and 25 μM for 24 h. Then, cells were washed with
pre-warmed 1X PBS and were incubated at 37 °C
with 10 μM DCFDA for 15 min in PBS. Subsequently,
PEL cells were washed and analyzed in FL-1 by a
FACScalibur flow cytometer (BD, USA), using CELL-
Quest software (BD Biosciences, San Jose, CA, USA).
Live cells were gated according to their forward scat-
ter (FSC) and side scatter (SSC) properties. For each
analysis 10.000 events were recorded [29].
Sub-G1 cell cycle analysis
For cell cycle analysis, the DNA content was analyzed
using the method of Propidium Iodide (Sigma
Aldrich, St Louis. MO, USA; P4170) staining and
flow cytometry. BC3 and BCBL1 untreated or treated
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with apigenin at 12.5 μM and at 25 μM for 24 h. 5 ×
105 cells were washed with cold 1X PBS and fixed in
70% ethanol on ice for at least 1 h. Cell pellet was
washed three times with cold 1X PBS and stained
with 50 μg/ml PI for 15 min at 37 °C. Then, DNA
content was measured by a BD Biosciences FACSCa-
libur. Cell debris was excluded from analysis by in-
creasing the forward scatter threshold. Cells with a
DNA content lower and a Side Scatter higher than
that of G0/G1 cells, were considered as apoptotic
cells, sub-G1. Data are representative of at least three
independent experiments.
Western blot analysis
1 × 106 cells were washed twice with 1X PBS solution
and centrifuged at 1500 rpm for 5 min. The pellet was
lysed in a RIPA buffer containing 150 mM NaCl, 1%
NP-40, 50 mM Tris-HCl (pH 8), 0.5% deoxycholic acid,
0.1% SDS, protease and phosphatase inhibitors. 20 μg of
protein lysates were subjected to protein electrophoresis
on 4-12% NuPage Bis-Tris gels (Sigma Aldrich, St Louis.
MO, USA; N00322BOX), according to the manufac-
turer’s instruction. Then, the gels were blotted onto
nitrocellulose membrane (Biorad, Milan, Italy; 162-0115)
for 2 h in Tris-Glycine buffer. The membranes were
blocked in PBS 0.1% Tween20 solution containing 3% of
BSA, probed with specific antibodies and developed
using ECL Blotting Substrate (Advansta, Menlo Park,
CA, USA; K-12045-D20).
Antibodies
In western blotting analysis, we used the following pri-
mary antibodies: rabbit polyclonal anti-PARP (1:500)
(Cell Signaling, Danvers, MA, USA; 9542), rabbit poly-
clonal anti p21 (1:100) (Santa Cruz Biotech, Heidelberg,
Germany; sc-397), mouse monoclonal anti-p53 (1:500)
(Santa Cruz Biotech, Heidelberg, Germany; sc-126),
mouse monoclonal anti-catalase (1:100) (Santa Cruz Bio-
tec, Heidelberg, Germany; sc-271,803), mouse monoclo-
nal anti-STAT3 (1:1000) (BD Transduction Laboratories,
New Jersey, USA; 610,189), mouse monoclonal anti-
phospho-STAT3 (p-Tyr705) (1:100) (Santa Cruz Biotec,
Heidelberg, Germany; sc-8059), rabbit polyclonal anti-
FLIP (1:100) (Santa Cruz Biotec, Heidelberg, Germany;
sc-8347), rabbit polyclonal anti-cMyc (1:500) (Cell Sig-
naling, Danvers, MA, USA; 5605) and rat polyclonal
anti-vFLIP (1:10)(4C1) (kindly provided by Prof. Regina
Feederle) [30]. To study autophagy, we used rabbit poly-
clonal anti-LC3 (1:1000) (Novus Biologicals, Cambridge,
UK; NB100-2220SS) and mouse monoclonal anti-p62
(1:500) (BD Transduction Laboratories, New Jersey,
USA; 610,883) antibodies.
Mouse monoclonal anti-β-actin (1:10,000) (Sigma
Aldrich, St Louis. MO, USA; A5441) (1:10,000) was
used as loading control. The goat polyclonal anti-
mouse IgG-Horseradish Peroxidase Santa Cruz Bio-
technology Inc., Heidelberg, Germany; sc-2005) and
anti-rabbit IgG-HRP (Santa Cruz Biotechnology Inc.,
Heidelberg, Germany; sc-2004) were used as second-
ary antibodies. All the primary and secondary anti-
bodies were diluted in PBS-0.1% Tween20 solution
containing 3% of BSA (SERVA, Reno, NV, USA;
11,943.03).
p53 silencing
BC3 cells, diluted in complete medium without antibi-
otics, were plated at a density of 3 × 105 cells/well in 12
wells plates. Then, cells were transfected with empty
vector [27] and si-p53 plasmid [28] using Lipofectamine
2000 (Thermo Fisher Scientific, Waltham, MA, USA;
1,880,845) for 48 h, according to the manufacturer’s in-
structions. Finally, BC3 cells were treated with apigenin
(12.5 μM) for the last 24 h and then centrifuged at 1500
rmp at 4C°. Cellular pellets were lysed and protein ex-
tracts were subjected to electrophoresis, as described
above.
Densitometric analysis
The quantification of proteins bands was performed by
densitometric analysis using the Image J software, down-
loaded from NIH web site (http://imagej.nih.gov).
Statistical analysis
Results are represented by the mean ± standard devi-
ation (SD) of at least three independent experiments
and a two-tailed Student’s t-test was used to demon-
strate statistical significance. Difference was consid-
ered as statistically significant when p-value was at
least <0.05.
Results
Apigenin induces apoptosis and autophagy in PEL cells
BC3, BCBL-1 PEL cell lines and B cells were treated
with two different concentration of apigenin (12.5 and
25 μM) for 24 h. We found that apigenin was able to
reduce PEL cell survival in a dose dependent fashion
while it slightly affected B cell survival, as indicated by
the trypan-blue exclusion assay (Fig. 1a and d). To
evaluate the type of cell death induced by apigenin, the
appearance of sub-G1 events was assessed by FACS
analysis. The increased percentage of sub-G1 events in
cells treated with different doses of apigenin (Fig. 1b)
suggests the occurrence of apoptotic cell death, con-
firmed by the cleavage of PARP observed by western
blot analysis (Fig. 1c). As autophagy is usually up-
regulated in cancer cells undergoing cytotoxic treat-
ments, we investigated whether apigenin could affect
autophagy in PEL cells. We found that LC3-II
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expression increased in PEL cells treated with apigenin
in presence of cloroquine in comparison with control
cells (Fig. 1e), indicating the induction of a complete
autophagic flux, further confirmed by the reduction of
p62 (Fig. 1f ), molecule mainly degraded through
autophagy.
Apigenin induced cell death correlates with the reduction
of intracellular ROS
Intracellular ROS may sustain the activation of pro-
survival pathways from which PEL cells are strongly
dependent [13, 26]. To corroborate this finding, we
treated PEL cells with the ROS scavenger N-
acetylcisteine (NAC) at two different doses (25 and
50 mM) and found that it reduced cell survival in a
dose-dependent fashion (Fig. 2a), Consequently, we
investigated whether apigenin could affect the levels of
intracellular ROS in PEL cells. As shown in Fig. 2b, api-
genin caused a dose-dependent ROS decrease in both
BC3 and BCBL-1 cells that correlated with the reduc-
tion of cell survival seen above (Fig. 1a and b) and simi-
larly to the effect achieved by NAC (see above). These
findings demonstrate the importance of ROS in the
maintenance of PEL cell survival and that apigenin,
similarly to NAC, can target it.
Apigenin activates p53 up-regulating p21 and catalase
expression in PEL cells
Apigenin has been reported to activate p53 oncosup-
pressor function in wild-type (wt)- or mutant 53-
carrying cancer cells [31, 32]. Therefore, here we eval-
uated whether apigenin could activate p53 in PEL.
Fig. 1 Apigenin induces apoptotic cell death and autophagy in PEL cell lines. BC3 and BCBL1 cell were treated with apigenin at the indicated
concentrations (12,5 and 25 μM) for 24 h. a Cell survival was assessed by trypan blue exclusion assay. The histograms represent the mean of the
percentage of cell survival plus SD of at least three independent experiments. *p< 0.05. b DNA content of PEL cell lines treated with apigenin
(12,5 and 25 μM) for 24 h as measured with Propidium Iodide staining and analyzed by flow cytometry. The percentage of sub-G1 events is
reported. FACS plots are representative of at least three independent experiments. Means plus SD of three independent experiments are: BC3 CT
5 ± 0.7, BC3 Api 12,5 28 ± 4, BC3 Api 25 73 ± 7; BCBL1 CT 3 ± 1, BCBL1 Api 12,5 24 ± 4, BCBL1 Api 25 75 ± 9; c The expression levels PARP uncleaved and
cleaved (clPARP) were assessed by western blot analysis. β-Actin was used as loading control. Numbers are calculated by quantitative densitometric
analysis and indicate the ratio of clPARP versus β-Actin. d Cell survival of primary B lymphocytes as assessed by trypan blue exclusion assay.
The histograms represent the mean of the percentage of cell survival plus SD of at least three independent experiments. *p< 0.05. e PEL cells
were treated with apigenin at 12,5 μM or chloroquine (CQ) at 10 nM and with both of them for 24 h and LC3-I/II expression was evaluated by
western blotting. Numbers are calculated by quantitative densitometric analysis and indicate the ratio of LC3-II versus β-Actin. f BC3 and BCBL1 were
treated with apigenin and p62 expression was evaluated by western blotting. Numbers are calculated by quantitative densitometric analysis and
indicate the ratio of p62 versus β-Actin. Data are representative of at least three independent experiments
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We found that apigenin treatment in BC3 and BCBL-
1 up-regulated the levels of p21, target of p53, in
comparison to the control cells (Fig. 3a); moreover,
we also found that apigenin increased protein levels
of catalase (Fig. 3a), one of the most important ROS
scavenger enzymes reported to be activated by p53
[24, 33]. Next, p53 silencing in BC3 cells impaired
both p21 and catalase up-regulation following api-
genin treatment (Fig. 3b) and partially prevented
apigenin-induced cell death as shown by viability and
PARP cleavage (Fig. 3c and d). Altogether these results in-
dicate that apigenin activated p53 to induce PEL cell death
likely through reduction of intracellular ROS production
by catalase.
Apigenin, by diminishing ROS, reduces STAT3 activity
Intracellular ROS are important to maintain cancer
cell survival through the activation of oncogenic path-
ways such as STAT3 [33] that is strongly involved in
PEL cell survival [11–13]. Therefore we evaluated
whether apigenin could modify STAT3 activation and
found that it strongly reduced STAT3 phosphorylation
in both BC3 and BCBL1 cells (Fig. 4a), similarly to
the effect achieved by the ROS scavenger NAC
(Fig. 4b).
STAT3 is an important transcription factor that regu-
lates the expression of a variety of pro-survival mole-
cules, including c-myc and cyclin D1 [14]. Based on this
knowledge we found that apigenin reduced c-myc and
cyclin D1 levels in PEL cells (Fig. 4c). Then, we investi-
gated if, besides molecules involved in cell proliferation,
apigenin could also affect cellular or viral molecules that
negatively regulate apoptosis. As shown in Fig. 4d, the
expression of cellular (c)-FLIP, also regulated by STAT3
[34], and viral (v)-FLIP, important anti-apoptotic mol-
ecule, were reduced following apigenin treatment.
Altogether, these findings suggest that apigenin, by tar-
geting STAT3, could modulate pro-survival and anti-
apoptotic pathways mainly regulated by STAT3 to
achieve cell death in PEL.
Fig. 2 Apigenin reduces intracellular ROS. a BC3 and BCBL1 cells were treated with NAC at 25 and 50 mM for 24 h. Cell survival was assessed by
trypan blue exclusion assay. The histograms represent the mean of the percentage of cell survival plus SD of at least three independent experiments.
*p< 0.05. b PEL cell were treated with apigenin at 12,5 and 25 μM for 24 h. Intracellular ROS were evaluated by FACS analysis using DCFDA staining
FACS plots are representative of three independent experiments. Numbers indicate the mean of fluorescence intensity. Means plus SD of
three independent experiments are: BC3 CT 540 ± 31, BC3 Api 12,5 μM 313 ± 21, BC3 Api 25 μM 193 ± 20; BCBL1 CT 1185 ± 90, BCBL1 Api 12,5
μM 724 ± 52, BCBL1 Api 25 μM 525 ± 33
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p53 activation by apigenin is involved in STAT3
dephosphorylation and STAT3 inhibition reduces its
negative influence on p53
As apigenin activated p53 and inhibited STAT3, we next
evaluated whether a cross-talk existed between these
two pathways, by performing p53 silencing. We found
that, compared to the empty vector (EV), p53 silencing
(sip53) rescued STAT3 phosphorylation in apigenin-
treated BC3 cells (Fig. 5a), confirming the role of p53 in
STAT3 inhibition. Since it has been reported that consti-
tutively activated STAT3 can negatively influence p53
activity [20], we investigated whether the pharmaco-
logical inhibition of STAT3 by AG490 could in turn in-
duce p53 activation. As shown in Fig. 5b, the efficient
reduction of STAT3 phosphorylation by AG490 treat-
ment correlated with up-regulation of p21 levels indica-
tive of p53 activation. Altogether, these findings
highlight the occurrence of a cross-talk between p53 and
STAT3 during apigenin treatment that modulates PEL
cell survival.
Discussion
PEL, the KSHV-associated B cell lymphoma, is highly
malignant and characterized by poor response to che-
motherapies. In this study, we show that apigenin could
represent a valid therapeutic strategy against PEL, also
confirming a previous reported study [7]. Apigenin is a
flavonoid widely distributed in plant kingdom display-
ing several beneficial effects also against cancer [3, 35–
37]. We found that, among the underlying mechanisms
leading to PEL cell death, apigenin induced a cross-talk
between p53 and STAT3. Indeed apigenin induced the
activation of p53, as revealed by p21 up-regulation, and
induced catalase expression, reducing ROS, dephos-
phorylating STAT3 and preventing STAT3 inhibitory
influence on p53 (Fig. 6). Although the influence of p53
on STAT3 [21] and of STAT3 on p53 [20], have been
previously described, this study shows, for the first
time, a cross-talk between the two pathways mediated
by the reduction of intracellular ROS. p53 is strongly
involved in the control of ROS level, since it can have
both pro-oxidant and anti-oxidant properties that can
be mediated by the inhibition or the activation of cata-
lase activity [38]. The finding that apigenin, by activat-
ing the anti-oxidant response, reduced PEL cell survival
is quite surprising, since it usually elevated oxidant spe-
cies to induce cancer cell death [39]. However, it is well
known that ROS levels need to be finely regulated since
either their increase or their reduction reduce cell sur-
vival [23]. In one hand, high levels of ROS sustain
Fig. 3 Apigenin activates p53 leading to an increase of catalase expression. a BC3 and BCBL1 cell lines were treated with apigenin 25μM for 24 h.
p53, p21 and catalase expression was assessed by western blotting analysis. β-Actin was used as loading control. Numbers are calculated by
quantitative densitometric analysis and indicate the ratio of specific proteins versus β-Actin. Data are representative of at least three independent
experiments. b BC3 cells were transiently transfected with si-p53 vector to silence p53 protein for 48 h and treated with apigenin 25 μM for the
last 24 h. p53, p21 and catalase expression was evaluated by western blotting. Numbers are calculated by quantitative densitometric analysis and
indicate the ratio of specific proteins versus β-Actin. Data are representative of at least three independent experiments. c p53-silenced or control
BC3 cell survival was assessed by trypan blue exclusion assay. The histograms represent the mean of the percentage of cell survival plus SD of at
least three independent experiments. *p< 0.05. d The expression levels PARP uncleaved and cleaved (ClPARP) were assessed by western blot
analysis in p53-silenced or control BC3 cells. β-Actin was used as loading control. Numbers are calculated by quantitative densitometric analysis
and indicate the ratio of clPARP versus β-Actin
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oncogenic signaling, indeed PEL cells die when ROS
decrease following treatment with metformin [26] or
with NAC, while on the other hand ROS increase may
also lead to cancer cell death, although cancer cells are
equipped with high expression of molecules, such
NRF2, that allow them to rapidly adapt to ROS
increase.
STAT3, one of the pathway strongly sustained by
ROS, is constitutively activated in PEL cells and plays
a fundamental role for the survival of these cells, as
well as of several other cancer cell types [13, 40]. It in-
deed may promote the transcription of a variety of
pro-survival molecules such as survivin, c-myc and
cyclin D1. Interestingly, STAT3 also interacts with
AKT/mTOR pathway in PEL cells, indeed they can
positively influence each other to promote cell survival
and both are sustained by high levels of intracellular
ROS [9, 10, 33]. On the other hand, ROS production is
influenced by the expression of KHSV proteins such
as v-FLIP [41], strongly down-regulated by apigenin,
similarly to its cellular homologue c-FLIP. C-FLIP and
v-FLIP are molecules involved either in the inhibition
of apoptosis and of autophagy [42–44], therefore their
down-regulation may contribute to the induction of
both processes by apigenin in PEL cells. However, the
inhibition of STAT3 is likely one of the main stimuli
leading to autophagy induction by apigenin and indeed
its activation, by regulating the release of cytokines by
cancer cells [9] as well as by immune cells [45], may
result in autophagy inhibition [46]. STAT3 activation
and autophagy inhibition also correlated with an im-
pairment of DC phenotypic and functional properties
[45], besides interfering with other aspects of the im-
mune response for which the autophagic process is
also required [47]. Regarding cancer cells, autophagy
activated by chemotherapies before or concomitantly
with apoptosis can influence cell survival either posi-
tively, by helping cells to cope with basal or
chemotherapy-induced stress, or negatively, by pro-
moting the degradation of oncogenic molecules such
as mutant p53 [48] or c-myc [10]. Furthermore, the ef-
fect of anti-cancer drugs on autophagy is worth to in-
vestigate, also beacause autophagy can promote the
release of ATP [49] and activate the immune system
and influence the overall survival of anti-cancer treat-
ments [50]. Regarding this point, there are increasing
Fig. 4 Apigenin de-regulating STAT3 activation, similarly to NAC, reduces the expression of pro-survival molecules c-myc, cyclin D1, cFLIP and
vFLIP. BC3 and BCBL1 were treated a with apigenin at 25 μM or b with NAC at 25 mM for 24 h and pSTAT3 (Tyr 705) and total STAT3 expression
were assessed by western blotting. β-Actin was used as loading control. Numbers are calculated by quantitative densitometric analysis and
indicate the ratio of phosphorylated (p-STAT3) versus total protein (STAT3) and total protein (STAT3) protein versus β-Actin. c c-myc and cyclinD1
and d cFLIP and vFLIP expression was assessed by western blot analysis in PEL cells treated with apigenin at 25 μM for 24 h. Numbers are
calculated by quantitative densitometric analysis and indicate the ratio of specific proteins (c-myc, cyclin D1, cFLIP and vFLIP) versus β-Actin. Data are
representative of at least three independent experiments
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evidences that the chemotherapy must not only be not
toxic for the cells of the immune system, but it should
also promote the exposure, or the release, of hidden
molecules called damage-associated molecular pat-
terns (DAMPs) that stimulate the immune response
against cancer [51].
Conclusions
In conclusion this study, showing the activation of a
cross-talk between p53 and STAT3 by apigenin, unveils
new molecular mechanisms through which this flavon-
oid leads to apoptosis and autophagy induction in PEL,
an aggressive lymphoma harboring wt p53 and constitu-
tive STAT3 activation, that is very difficult to success-
fully treat.
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